Insights

Strategic Partnerships Novome Biotechnologies is actively engaging with large biotech players and venture funds, evidenced by collaborations and investments from Genentech and Colorcon Ventures. This suggests a receptive environment for co-development, licensing, or strategic funding discussions with potential partners in gut microbiome therapeutics, manufacturing, and commercialization.

Clinical Milestones Lead program in enteric hyperoxaluria is in Phase 2 trials, highlighting near-term experimentation and potential for milestone-based partnerships, co-promotions, or out-licensing opportunities aligned with regulatory progress and patient recruitment timelines.

Platform Commercialization Novome’s platform for controlled colonization of the gut with engineered therapeutic bacteria indicates multiple expansion opportunities across disease areas. This creates cross-sell potential for contract development and manufacturing services and technology licensing for other firms pursuing GEMMs.

Funding-led Validation Recent $43.5 million Series B financing and prior investments signal investor validation and market credibility, making the company an attractive candidate for strategic investments, joint ventures, or collaborative grants with a focus on microbiome therapies and scalable manufacturing.

Operational Readiness While current employee count is lean, the use of established tech stack and success in securing funding suggests readiness to engage in early-stage pilot collaborations. Prospects include research collaborations, clinical development support, and shared regulatory or Biotech Ops partnerships to accelerate programs.

Similar companies to Novome Biotechnologies

Novome Biotechnologies Tech Stack

Novome Biotechnologies uses 8 technology products and services including Quickbooks Online, SciPy, WordPress, and more. Explore Novome Biotechnologies's tech stack below.

Media & News

Novome Biotechnologies's Email Address Formats

Novome Biotechnologies uses at least 3 email formats:
Novome Biotechnologies Email FormatsExamplePercentage
FLast@novomebio.comJDoe@novomebio.com
97%
First@novomebio.comJohn@novomebio.com
1%
FL@novomebio.comJD@novomebio.com
2%

Frequently Asked Questions

What is Novome Biotechnologies's official website and social media links?

Minus sign iconPlus sign icon
Novome Biotechnologies's official website is novomebio.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Novome Biotechnologies generate?

Minus sign iconPlus sign icon
As of October 2026, Novome Biotechnologies's annual revenue is estimated to be $1M - $10M.

What is Novome Biotechnologies's SIC code and NAICS code?

Minus sign iconPlus sign icon
Novome Biotechnologies's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Novome Biotechnologies have currently?

Minus sign iconPlus sign icon
As of October 2026, Novome Biotechnologies has approximately 1 employees across 1 continents, including North America. Key team members include Vp Of Research, Co-Founder: W. W. Explore Novome Biotechnologies's employee directory with LeadIQ.

What industry does Novome Biotechnologies belong to?

Minus sign iconPlus sign icon
Novome Biotechnologies operates in the Biotechnology Research industry.

What technology does Novome Biotechnologies use?

Minus sign iconPlus sign icon
Novome Biotechnologies's tech stack includes Quickbooks Online, SciPy, WordPress, NetSuite, Shopify, Google Cloud, jQuery Migrate and WP Engine.

What is Novome Biotechnologies's email format?

Minus sign iconPlus sign icon
Novome Biotechnologies's email format typically follows the pattern of FLast@novomebio.com. Find more Novome Biotechnologies email formats with LeadIQ.

How much funding has Novome Biotechnologies raised to date?

Minus sign iconPlus sign icon
As of October 2026, Novome Biotechnologies has raised $83M in funding. The last funding round occurred on Sep 13, 2022 for $44M.

When was Novome Biotechnologies founded?

Minus sign iconPlus sign icon
Novome Biotechnologies was founded in 2016.
Novome Biotechnologies logo

Novome Biotechnologies

Biotechnology ResearchCalifornia, United States0-1 Employees

Novome Biotechnologies operates in biotechnology research, focusing on genetically engineered microbial medicines designed to act in the human gut to treat chronic diseases. It has built a platform intended to enable controlled colonization of the gut with engineered therapeutic bacteria and to expand its capabilities across multiple disease areas. The lead program targets enteric hyperoxaluria and is in Phase 2 clinical trials, with ongoing work to develop a microbial cell therapy for inflammatory bowel disease.

Based in South San Francisco, California, the company operates with a small team in the biotechnology research sector focused on therapies designed to act in the gut. In 2021, Genentech entered into a collaboration with Novome Biotechnologies to explore a novel approach to a gut-related indication.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
0-1

Section iconFunding & Financials

  • $83M

    Novome Biotechnologies has raised a total of $83M of funding over 6 rounds. Their latest funding round was raised on Sep 13, 2022 in the amount of $44M as a Series B.

  • $1M - $10M

    Novome Biotechnologies's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.